SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

UPLOAD Filing

Rezolute, Inc.
Date: July 24, 2025 · CIK: 0001509261 · Accession: 0000000000-25-007838

Offering / Registration Process

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

File numbers found in text: 333-288731

Date
July 24, 2025
Author
Division of
Form
UPLOAD
Company
Rezolute, Inc.

Letter

Re: Rezolute, Inc. Registration Statement on Form S-3 Filed July 17, 2025 File No. 333-288731 Dear Nevan Elam:

July 24, 2025

Nevan Elam Chief Executive Officer Rezolute, Inc. 275 Shoreline Drive, Suite 500 Redwood City, CA 94065

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Tyler Howes at 202-551-3370 with any questions.

Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: Anthony W. Epps, Esq.

Show Raw Text
<DOCUMENT>
<TYPE>TEXT-EXTRACT
<SEQUENCE>2
<FILENAME>filename2.txt
<TEXT>
 July 24, 2025

Nevan Elam
Chief Executive Officer
Rezolute, Inc.
275 Shoreline Drive, Suite 500
Redwood City, CA 94065

 Re: Rezolute, Inc.
 Registration Statement on Form S-3
 Filed July 17, 2025
 File No. 333-288731
Dear Nevan Elam:

 This is to advise you that we have not reviewed and will not review your
registration
statement.

 Please refer to Rules 460 and 461 regarding requests for acceleration.
We remind you
that the company and its management are responsible for the accuracy and
adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action
by the staff.

 Please contact Tyler Howes at 202-551-3370 with any questions.

 Sincerely,

 Division of
Corporation Finance
 Office of Life
Sciences
cc: Anthony W. Epps, Esq.
</TEXT>
</DOCUMENT>